Nytyka (Nintedanib)

Nytyka (nintedanib) is used in fibrotic lung diseases and selected oncology indications, targeting pathways that drive fibroblast activity and tumor angiogenesis.

• Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression.
• Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and stabilizes respiratory status.
• Non‑small cell lung cancer: used with chemotherapy to inhibit tumor growth in patients with appropriate disease characteristics.

• Nintedanib inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR 1‑3), fibroblast growth factor receptors (FGFR 1‑3), and platelet‑derived growth factor receptors (PDGFR α/β). By blocking these signaling pathways, the drug reduces fibroblast proliferation, angiogenesis, and extracellular matrix deposition, thereby limiting fibrotic remodeling in the lung and impairing tumor vascular support. This multi‑target inhibition also contributes to anti‑tumor activity by starving neoplastic cells of nutrients.

Nintedanib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools often occurring early in treatment.
• Nausea: feeling of sickness that may affect appetite.
• Vomiting: occasional expulsion of stomach contents.
• Abdominal pain: discomfort or cramps in the stomach area.
• Decreased appetite: reduced desire to eat.
• Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury requiring monitoring.
• Bleeding events: gastrointestinal or other hemorrhage.
• Cardiovascular events: arterial thrombotic episodes.
• Gastrointestinal perforation: rare but serious intestinal rupture.
• Severe infections: opportunistic infections in immunocompromised patients.
• Hypersensitivity reactions: rash, fever, or anaphylaxis.

When prescribing Nytyka, clinicians should observe several precautionary measures to ensure patient safety.

• Liver function monitoring: assess baseline ALT/AST and repeat regularly during therapy.
• Bleeding risk assessment: evaluate concomitant anticoagulant or antiplatelet use before initiating treatment.
• Cardiovascular evaluation: screen for history of arterial thrombotic disease.
• Gastrointestinal health: use caution in patients with ulcerative disease or recent GI surgery.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Nintedanib may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nintedanib exposure.
• Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels.
• Anticoagulants (e.g., warfarin): heightened risk of bleeding.
• Antiplatelet agents (e.g., aspirin, clopidogrel): increased hemorrhagic risk.

Moderate Interactions (Monitor Closely)

• P‑glycoprotein inhibitors (e.g., verapamil): may modestly raise plasma concentrations.
• CYP2C8 substrates (e.g., paclitaxel): potential for altered metabolism.
• Diuretics: monitor for electrolyte disturbances due to gastrointestinal losses.